Vancomycin-resistant enterococci (VRE) infections have been increasingly reported in immunosuppressed individuals over the past decade. Emergence of this pathogen in the bone marrow transplantation (BMT) setting, in the form of bacteremia or positive stool cultures, is of concern because of lack of effective antimicrobial therapy. We report episodes of vancomycinresistant E. faecium bacteremia in two patients undergoing BMT including the first case of VRE meningitis observed in this setting. Since the outcome in these patients undergoing matched unrelated donor BMT was fatal, we believe that routine screening for VRE in high risk patients should be considered. Management of VRE carrier state in BMT candidates is unclear at present. Keywords: VRE; bone marrow transplantation; meningitis Vancomycin-resistant enterococcal (VRE) infections are of potential concern for patients undergoing bone marrow transplantation.
Vancomycin-resistant enterococcal (VRE) infections are of potential concern for patients undergoing bone marrow transplantation. 1, 2 Over 10% of enterococci leading to infections are now resistant to vancomycin, and in intensive care units the incidence of nosocomial VRE infections has increased from 0.3% in 1989 to 10% in 1995. 3, 4 The risk factors for clinically significant VRE infections are severe underlying disease, immunosuppression, renal insufficiency, long duration of broad-spectrum antibiotic therapy and frequent use of oral or i.v. vancomycin in the hospital setting. 5 We report two cases of fatal VRE infection occurring in BMT patients, including the first reported case of VRE meningitis.
Fatal VRE infections have been reported in patients undergoing liver and kidney transplants but not in recipients of allogeneic bone marrow transplants (BMT). 2, 6, 7 Patients at high risk of VRE infection should be identified prior to transplant and admission to the bone marrow transplant unit. This will require periodic screening of surveillance cultures in immunosuppressed individuals at risk for VRE infection and immediate initiation of specific precautions in colonized patients to prevent nosocomial spread in institutions where this microorganism is endemic.
Case reports

Case 1
A 42-year-old female was diagnosed with CML in July 1995. After a temporary response to hydroxyurea, she presented in myeloid blast crisis with a WBC of 109 000/mm 3 . After failing conventional chemotherapy with fevers, 68% blasts in the peripheral smear and progressive splenomegaly despite splenic radiation, she was admitted to hospital in January 1996. A Hickman catheter was placed immediately after admission and the patient was started on imipenem and vancomycin prior to initiation of the induction regimen consisting of idarubicin and cytarabine. Fluconazole was added to the regimen on day 4 of antimicrobial chemotherapy because of persistent fevers. On day 5 of admission, she became afebrile, blood cultures were negative, and vancomycin and imipenem were discontinued on day 9. The patient was placed on prophylactic ciprofloxacin upon discontinuation of i.v. antibiotics. On day 16, she developed sinus tenderness associated with soft tissue edema of the left maxillary sinus and opacification of the left ethmoid sinus demonstrated by a head CT. She was started on amoxicillin/clavulanic acid in combination for sinusitis and ciprofloxacin was discontinued. Her symptoms improved on amoxicillin/clavulanic acid and decongestants.
The patient received 500 cGy of splenic irradiation administered over 5 days starting on day 21 in preparation for the planned matched unrelated donor transplant. On day 23, the patient developed fevers that led to re-initiation of vancomycin and imipenem therapy and amoxicillin/clavulanic acid was discontinued. Blood cultures drawn from the Hickman catheter and peripheral veins were positive for VRE (Enterococcus faecium) and Candida glabrata. She was placed on amphotericin-B at a dose of 0.45 mg/kg/day and the Hickman catheter was removed. A subclavian catheter was placed to maintain intravenous access. Since her clinical condition had been stable and the central line was removed, VRE bacteremia was not treated. Sur-veillance cultures including catheter insertion site and stool were negative for VRE. The patient remained febrile for 5 days on broad-spectrum antimicrobial therapy and amphotericin. Repeat blood cultures on day 25 of admission were still positive for Candida glabrata. The amphotericin dose was increased to 0.65 mg/kg and the subclavian line was replaced by a new Hickman catheter. She defervesced and subsequent blood and catheter skin site cultures were negative for Candida species or VRE. On day 26 (day −5 pretransplant), the patient received a preparative regimen of cyclophosphamide (60 mg/kg × 2) followed by 1200 cGy of total body irradiation (TBI) administered between days −3 and −1. Continuous infusion cyclosporin A and pulse dose methotrexate (MTX) were administered for graft-versus-host prophylaxis (GVHD). Matched unrelated marrow was infused on 8 February 1996 (day 0) and the patient remained stable and afebrile during the peri-transplant period. She developed grade II-III mucositis but remained afebrile on amphotericin, and vancomycin until day +10 post-transplant. Her renal function was impaired due to combined nephrotoxic effects of cyclosporin A and amphotericin. On day +11, she developed a fever rising to 39°C. Blood cultures drawn from the new Hickman catheter, subclavian line and peripheral veins grew identical strains of VRE (E. faecium). The Hickman catheter was removed and the catheter tip culture was negative for VRE. Vancomycin was discontinued and chloramphenicol 500 mg i.v. every 6 h, to which the organism was sensitive, was started. She remained febrile over the next 6 days with increasing bilirubinemia and declining renal function. Repeated blood cultures continued to grow VRE on chloramphenicol therapy until day +19. An echocardiogram done on day +15 did not show any abnormality in the cardiac valves. Hemodialysis was started and she was afebrile after day +17. The patient engrafted on day +20 with a WBC of 1000 mm 3 and an absolute neutrophil count (ANC) of 500 mm 3 , after 7 weeks of absolute granulocytopenia following hospital admission. On day +21, the patient had a grand mal seizure associated with a fever of 40.3°C. The cerebrospinal fluid (CSF) examination revealed an elevated protein level (234 mg/dl) with a neutrophilic leukocytosis (WBC: 60/mm 3 , 78% neutrophils). The CSF culture was positive for the same strain of VRE as determined by identical antibiogram profile including gentamicin-streptomycin synergism and colonial morphology. After obtaining informed consent, quinupristin/dalfopristin (Synercid, 7.5 mg/kg i.v.; RhonePoulenc Rorer, Collegeville, PA, USA), an investigational drug used for the treatment of VRE infections was started. 8 The isolates from previous blood cultures were sensitive to this antibiotic. Repeat echocardiogram showed global hypokinesis but was negative for valvular vegetation. Her mucositis, liver and renal functions gradually improved. Dialysis was no longer required. On day +26, she complained of a severe headache and blood and CSF cultures were positive for VRE. On day +30, the patient developed hypothermia, hypoxia and a rapidly declining mental status. A repeat head CT scan showed hydrocephalus, which was not detected in the head CT performed 10 days earlier. A new harsh holosystolic murmur was noted and an echocardiogram demonstrated vegetations on the tricuspid valve. Her clinical condition continued to deteriorate and the patient expired on post-transplant day +33. Blood cultures drawn 48 h prior to the patient's death were positive for VRE. Permission for an autopsy was declined by her relatives.
Case 2
A 33-year-old white female was diagnosed with AML in September 1995 when she presented with a WBC of 164 000/mm 3 and a pharyngeal abscess. She was treated with emergency leukapheresis followed by induction chemotherapy. The induction course was complicated with cerebellar toxicity secondary to high-dose cytarabine. She attained a complete remission and received an autologous bone marrow transplant in January 1996 after receiving two cycles of consolidation chemotherapy.
The patient relapsed with AML in August 1996 and underwent a second induction chemotherapy with idarubicin and cytarabine. Surveillance stool cultures for VRE were negative prior to admission. This was complicated by a painful erythematous rash of the hands and feet, fevers thought to be secondary to Ara-C, but treated with broadspectrum antibiotics including vancomycin and ceftazidime prior to discharge. She was re-admitted during the neutropenic period because of painful oral ulcers, headache, nausea and vomiting, abdominal pain and rhinorrhea. She developed fever and was placed on vancomycin, ceftazidime and amphotericin while neutropenic. A bone marrow biopsy performed on day +17 of the induction regimen revealed residual leukemia. In October 1996, she was admitted for matched unrelated donor transplant. She received a preparative regimen of cyclophosphamide (60 mg/kg × 2) and TBI (1200 cGy) followed by continuous infusion CsA and pulse dose MTX for GVHD prophylaxis. The patient received marrow infusion on 21 October 1996 (day 0). She developed grade II-III mucositis and Staphylococcus epidermidis bacteremia during the early posttransplant period. On day +10, she was febrile to 38.8°C and blood cultures grew VRE (E. faecium) sensitive to chloramphenicol. The Hickman catheter was removed and replaced by a subclavian line. Surveillance cultures including urine and catheter tip cultures were negative for VRE. She remained febrile to 39°C while receiving ceftazidime, amphotericin, tobramycin and chloramphenicol. Multiple blood cultures drawn from the new central line and peripheral veins continued to grow VRE between days +10 and +20. After informed consent, quinupristin/dalfopristin (Synercid) was started. She engrafted on day +18 with a WBC of 1000/mm 3 and an ANC of 480/mm 3 . Her blood cultures continued to grow VRE. All intravenous lines were changed, catheter tip cultures remained negative. Echocardiogram showed moderate global hypokinesis without evidence of valvular vegetations. On day +20, the patient developed progressive respiratory and renal failure. The repeat blood cultures drawn on day +20 were again reported to be positive for the same strain of VRE. The chest X-rays showed progressive multiple and bilateral nodular infiltrates consistent with septic pulmonary emboli. She was transferred to the intensive care unit and started on mechanical ventilation as she progressed into a clinical picture of respiratory distress syndrome. Chloramphenicol was added to the antibiotic regimen. She became hypotensive despite supportive therapy and expired on day +23 following the transplant. A needle biopsy from the left lung performed immediately after the patient's death revealed the presence of macrophages. Tissue cultures from the lung biopsy were negative for fungal or mycobacterial infection. VRE was not recovered from the needle biopsy of the lung.
Discussion
The two reported cases of fatal VRE infections illustrate the emerging problem of VRE infections in patients following an allogeneic BMT. These patients had multiple cytotoxic chemotherapy cycles with radiation therapy and complicated transplant courses. Both patients developed severe mucositis and received prolonged courses of multiple broad-spectrum antibiotics including vancomycin. In casecontrolled studies of kidney and liver transplant patients there was an association between VRE colonization and infection and the prior use of vancomycin; the administration of third generation cephalosporins; the development of renal failure and the severity of the patient's illness. 1, [5] [6] [7] 9 However, VRE colonization was not consistently associated with an increased mortality or morbidity in kidney and liver transplant recipients. 2, [5] [6] [7] In contrast to the single previously reported case of VRE bacteremia in a BMT patient, who responded to removal of an infected catheter, our patients remained persistently bacteremic despite appropriate antibiotics and removal of intravenous lines. 10 Although multiple catheter tip cultures from the removed central lines were always negative for VRE in the first case, there was strong evidence suggestive of right-sided endocarditis most likely secondary to persistent bacteremia not responding to the antibiotic regimens instituted. Emergence of VRE endocarditis in a patient on chronic hemodialysis possibly due to routine use of vancomycin in this patient group with renal failure has been reported recently. 11 In case 1, the patient developed VRE meningitis despite treatment with chloramphenicol and the course of the meningitis did not change on the investigational agent, Synercid. The VRE meningitis was rapidly progressive despite treatment with antibiotics to which the organism was sensitive in vitro. We believe that this is the first reported case of VRE meningitis. In case 2, blood cultures drawn 3 days prior to death were positive for VRE. Tissue cultures obtained from the lung immediately after death were negative for fungal or mycobacterial infections. However, a full autopsy was not obtained. In this case, the chest X-rays showed rapidly progressive nodular infiltrates in both lungs. It is very likely that the cause of death was overwhelming VRE sepsis and/or pulmonary septic emboli leading to adult respiratory distress syndrome.
The cases reported demonstrate the difficulty in treating patients with VRE following allogeneic BMT. The two patients did not respond to systemic antibiotics and died as a consequence of the VRE infection. The incidence of VRE is increasing and the nosocomial spread of VRE in transplant units is a serious potential problem. To prevent nosocomial infections, precautions directed against VRE contamination remain the only effective measure. 12 These include isolation of colonized patients, use of protective gowns and gloves and avoiding routine use of vancomycin for prophylaxis. 1, 12 Patients who are colonized with VRE may be at higher risk of transplant-related complications and VRE infection. Restriction of intravenous or oral vancomycin use has not yet been shown to decrease the colonization rate with VRE. 1 Enterococci can survive for prolonged periods on environmental surfaces including bed rails, and stethoscopes. 1, 3 Identification of patients colonized with VRE may decrease the risk of nosocomial spread.
